All You Can Innovate logo

Our Imperial Confidence in Concept launch event - 19 February 2019


ICiC Showcase Event - 19 February 2019

We are pleased to announce the 2019 ‘All You Can Innovate’, which is our Imperial Confidence in Concept launch event.

The event will include presentations, posters and demonstrations about translational research at Imperial, industry engagement possibilities and funding opportunities.
It will also include an opportunity for individual academics and industry to meet and discuss potential collaborations, during the ‘Corporate Speed Dating’ component of the day.

In addition, we’ll be holding  support team surgeries to provide attendees with the chance to talk to other key parties. This includes funders such as the MRC and Imperial support resources including Research Strategy, Corporate Partnerships, Innovations, Apollo and the College’s Translator in Residence.

All You Can Innovate 2019
 Tuesday 19 February 2019

 10 am registration
- 10.30am opening

Translation and Innovation Hub (IHUB) - 10th Floor
White City Campus
80 Wood Lane
London W12 0BZ
More information will be available shortly
Summary of the table's contents


The MRC ‘Confidence in Concept’ scheme awards universities grants of up to £1.2M to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach. These awards ‘pump-prime’ the translation of novel therapeutics, devices and diagnostics, including ‘repurposing’ of existing therapies towards clinical testing.

The College has been recently awarded £944,000 from MRC to support projects through the ICiC scheme to bridge the gap between discovery research and well-developed applications for MRC Developmental Pathway Funding Scheme (DPFS) support or similar follow-on funding schemes.

Together with support from the NIHR Imperial BRC, The Royal Marsden Hospital NHS Foundation Trust, the Imperial College Wellcome Institutional Strategic Support Fund (ISSF) and Impact Acceleration Accounts, there will be a project-managed fund of £1.8M available in 2018 to identify early targets, not currently being developed, within the Faculties of Medicine, Natural Sciences and Engineering to enter the drug, devices and diagnostics development pathway.

In 2018 we will again be partnering with AstraZeneca to offer the AstraZeneca Innovation Fund as part of the Imperial Confidence in Concept call.  The AZ innovation fund aims to enable drug discovery by facilitating the development of new technologies and the exploration of disease biology. In 2018 the scheme will fund up to 3 proof of concept collaborative projects between AZ and ICL. All projects must have a PI from Imperial and AZ to qualify.  Projects should investigate new science or demonstrate proof of concept for new technology capabilities with the primary objective of seeding larger funding applications. Key areas of interest to AZ in 2018 are: Organ on a Chip (Microphysiological Systems), Next Generation Drug Delivery Technologies, Future Technologies for Early Drug Discovery, New Technologies for Patient Stratification and Diagnostics.’

Applying for the scheme

Current call - CLOSED

This call is currently closed to applications; the next call will be announced Jan/Feb 2019.

Guidance on the application process is available through the ICiC 2018 Guidelines (PDF) and ICiC FAQs 2018 (PDF). For further information and to submit your ICiC 2018 EoI form (Word) please contact

Previously supported projects

Year 1

Principal InvestigatorProject
Charles Coombes Understanding the Role of CDK9 in mediating resistance to CDK7 inhibitors and optimisation of CDK9 inhibitors
Michael Edwards  Uncoupling harmful pro-inflammatory cytokine responses from beneficial anti-viral immunity in virus induced exacerbations of asthma and COPD
Georgios Giamas  Drug screening, crystallisation and structure determination of the human Lemur Tyrosine Kinase 3
Uta Griesenbach Airway epithelium as a factory for production of blood clotting factors
Pau Herrero Vinas Clinical Validation of an advanced bolus calculator for diabetes
Prapa Kanagaratnam ROTO-Mapping: A technique for detecting potential rotos of activation during human atrial fibrillation
Nicholas Long Formyl peptide receptors: novel targets for imaging inflammation
Nick Oliver Clinical Assessment of a Novel Microprobe Array Continuous Glucose Monitor in Type 1 Diabetes
Gregory Quinlan Development of the haemolysis triple filter
Michael Schneider Novel inhibitors of MAP4K4 (HGK), a therapeutic target in cardiac muscle cell death
Mohamed Shamji IL-35 modulate allergen-driven memory human TH2 allergic responses and has a potential therapeutic value in patients with seasonal allergic rhinitis
Anita Simonds Evaluation intelligent oxygen therapy [chronic hypoxaemia/COPD]
Robert Snelgrove Manipulating the dual functions of LTA4H: one drug to target two pro-inflammatory mediators tightly implicated in neutrophilic lung disease
Shiranee Sriskandan Novel protective antigens in pathogenic group A Streptococcus
Molly Stevens A quantum-dot biosensor system for the detection of myocardial fibrosis biomarkers in clinical samples
Euan Stronach Novel chemical modulators of platinum response in ovarian cancer: characterisation and development of DNA-PK/AKT pathway inhibitors
Simon Taylor-Robinson A novel, low cost, urinary diagnostic test for liver cancer screening
Mark Thursz Phosphodiesterate 12 (PDE12) inhibitors in-vivo proof-of-concept study in Dengue virus (DENV) mouse model
Sivaramesh Wigneshweraraj Bacteriophage inspired antibiotics

Year 2

Principal InvestigatorProject
Jake Baum Towards an in vitro high-throughput translation-inhibition discovery platform for the malaria parasite Plasmodium falciparum
Maria Belvisi TRPV4 antagonist: novel, effective treatment for asthma and COPD
Paul Bentley A low-cost, portable ‘hand-and-brain training’ stroke rehabilitation aid
Bob Brown & David Cunningham Stratified Medicine in oesophagastric (OG) cancers: DNA methylation and mutational profiles as predictive biomarkers
Tony Cass Continuous monitoring of therapeutic drug levels using minimally invasive plasmonic nanosensors
Robert Dickinson Is xenon combined with hypothermia neuroprotective following traumatic brain injury?
Andrew Edwards Novel Antibiotics Activated By Beta-Lactamase: Treating and Preventing Infection By Directing Bacterial Evolution
Dan Elson Calibration-free structured lighting for flexible gastrointestinal endoscopy
Matthew Fuchter The Development of Highly Specific SIRT2 Inhibitors as a Novel Treatment for Parkinson’s Disease
Roger Gunn Repurposing Low-Cost Consumer Technology for Motion Correction in Dementia Neuroimaging
Anastasios Karadimitris Donor TCRVa24 iNKT cells in the prevention of acute-graft-versus-host disease in allogeneic haemopoietic stem cell transplantation
Maurits Kleijnen Proteasome Envelope Agonists: Developing novel compounds for use against Multiple Myeloma
Spyros Masouros Bespoke synthetic grafts for the treatment of an osteochondral defect that maximizes bone stock preservation
Thomas McKinnon Application of a truncated Von Willebrand Factor molecule for gene therapy for Von Willebrands disease
James Moore Jr Lymph node replacement tissue construct
Niamh Nowlan A wearable sensor for monitoring fetal movements
Nicholas Peters Identifying the critical concurrent sources for targeting ablation of atrial fibrillation through a novel spatiotemporal cycle-length decomposition
Piero Posocco Towards a compact proton irradiator for in-vitro radiobiological studies
Robert Snelgrove Manipulating the dual functions of LTA4H: one drug to target two pro-inflammatory mediators - Proof of concept in neutrophilic lung disease models
Molly Stevens Quantum-dot DNA Biosensing System for Meningococcal DNA Detection in Human Serum
Ed Tate Establishing the chemotherapeutic scope of novel, orally active inhibitors of human N-myristoyltransferases in cancer
Paul Turner Intranasal diagnostics in food allergy: a feasibility study (INDY project)
Sivaramesh Wigneshweraraj Characterization of two novel small molecule inhibitors of the bacterial transcription machinery